Scopus
YÖKSİS DOI Eşleşti
SJR Q2
In vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery
Pharmaceutical Development and Technology · Temmuz 2020
YÖKSİS Kayıtları
In vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery
Pharmaceutical Development and Technology · 2020 SCI-Expanded
Dr. Öğr. Üyesi SEMA ARISOY →
YÖKSİS Kayıtları — ISSN Eşleşmesi
Development of ACE2 loaded decoy liposomes and their effect on SARS-CoV-2 for Covid-19 treatment
2022 ISSN: 1083-7450 SCI-Expanded Q3
Arş. Gör. MERYEM KOÇAŞ →
Development of ACE2 loaded decoy liposomes and their effect on SARS-CoV-2 for Covid-19 treatment
2022 ISSN: 1083-7450 SCI-Expanded Q2
Dr. Öğr. Üyesi SEMA ARISOY →
Ivermectin-based therapeutics: modern dosage forms and drug delivery innovations
2025 ISSN: 1083-7450 SCI-Expanded Q2
Arş. Gör. MERYEM KOÇAŞ →
Makale Bilgileri
ISSN10837450
Yayın TarihiTemmuz 2020
Cilt / Sayfa25 · 735-747
Scopus ID2-s2.0-85082179525
Özet
Parkinson’s disease (PD) is a neurodegenerative disease which is characterized by the loss of dopaminergic neurons in the brain. Levodopa is the drug of choice in the treatment of PD but it exhibits low oral bioavailability (30%) and very low brain uptake due to its extensive metabolism by aromatic amino acid decarboxylase in the peripheral circulation. Moreover, levodopa has psychic, gastrointestinal, and cardiovascular side effects, and most importantly, short and frequent stimulation of dopamine receptors lead to undesirable conditions such as dyskinesia over time. The challenges are to increase the therapeutic efficiency, the bioavailability and decreasing the unfavourable side effects of levodopa. Biocompatible nano-sized drug carriers could address these challenges at molecular level. For this purpose, levodopa-loaded Poly (lactide-co-glycolide) acid nanoparticles were prepared by double emulsion-solvent evaporation method for nose to brain drug delivery. Parameters such as homogenization speed, and external and internal phase content were modified to reach the highest loading efficiency. F1-1 coded formulation showed prolonged release up to 9 h. Carbodiimide method was used for surface modification studies of nanoparticles. The efficacy of the selected nanoparticle formulation has been demonstrated by in vivo experiments in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced PD model in mice.
Yazarlar (5)
1
Sema Arisoy
ORCID: 0000-0003-2798-1884
2
Tansel Comoglu
ORCID: 0000-0002-4221-5814
3
Deniz Onal
4
Ozbeyen Atalay
5
Bilge Pehlivanoglu
Anahtar Kelimeler
in vivo Parkinson disease model
levodopa nanoparticles
Nasal drug delivery
Parkinson disease
PLGA
wheat germ aglutinine conjugation
Kurumlar
Ankara Üniversitesi
Ankara Turkey
Hacettepe Üniversitesi
Ankara Turkey
Inönü Üniversitesi
Malatya Turkey
Scimago Dergi (ISSN Eşleşmesi)
Pharmaceutical Development and Technology
Q2
SJR Skoru0,463
H-Index74
YayıncıInforma Healthcare
ÜlkeUnited States
Pharmaceutical Science (Q2)
Medicine (miscellaneous) (Q3)
Metrikler
86
Atıf
5
Yazar
6
Anahtar Kelime